BACKGROUND: Total body irradiation (TBI) is an important component of hematopoietic stem cell transplant (SCT) for pediatric malignancies. With increasing survival rates, late effects of SCT become more important. Younger children may be at particular risk of late effects of radiation and SCT. METHODS: We retrospectively reviewed outcomes of children less than 3 years of age who received TBI as part of their preparative regimen for SCT at Children's Hospital Colorado. Clinical information including the date of last follow-up, most recent lab values, and physiologic tests were extracted from the medical record. RESULTS: Of 81 patients who underwent SCT, 19 received TBI and of those, 15 were long-term survivors available for review. Late effects occurring in greater than 50% of the children included abnormalities involving endocrine, metabolic, renal, cataracts, and neurocognitive systems. Other organs involved less commonly included liver, skeletal, and cardiac abnormalities. Solid tumors were a rare finding with only one patient developing a benign osteochondroma and no identified secondary malignancies. CONCLUSIONS: TBI has been shown to be an important part of the preparative regimen for patients undergoing SCT. Our results, similar to other studies, suggest TBI in patients less than 3 years of age will likely result in multi-organ dysfunction including endocrine, metabolic, renal, eye, and neurocognitive abnormalities. A longitudinal study with standardized testing of these systems would further clarify the late effects concerns in this patient population.
BACKGROUND: Total body irradiation (TBI) is an important component of hematopoietic stem cell transplant (SCT) for pediatric malignancies. With increasing survival rates, late effects of SCT become more important. Younger children may be at particular risk of late effects of radiation and SCT. METHODS: We retrospectively reviewed outcomes of children less than 3 years of age who received TBI as part of their preparative regimen for SCT at Children's Hospital Colorado. Clinical information including the date of last follow-up, most recent lab values, and physiologic tests were extracted from the medical record. RESULTS: Of 81 patients who underwent SCT, 19 received TBI and of those, 15 were long-term survivors available for review. Late effects occurring in greater than 50% of the children included abnormalities involving endocrine, metabolic, renal, cataracts, and neurocognitive systems. Other organs involved less commonly included liver, skeletal, and cardiac abnormalities. Solid tumors were a rare finding with only one patient developing a benign osteochondroma and no identified secondary malignancies. CONCLUSIONS: TBI has been shown to be an important part of the preparative regimen for patients undergoing SCT. Our results, similar to other studies, suggest TBI in patients less than 3 years of age will likely result in multi-organ dysfunction including endocrine, metabolic, renal, eye, and neurocognitive abnormalities. A longitudinal study with standardized testing of these systems would further clarify the late effects concerns in this patient population.
Authors: M L van Kempen-Harteveld; H Struikmans; H B Kal; I van der Tweel; M P Mourits; L F Verdonck; J Schipper; J J Battermann Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: S M Davies; N K Ramsay; J P Klein; D J Weisdorf; B Bolwell; J Y Cahn; B M Camitta; R P Gale; S Giralt; C Heilmann; P J Henslee-Downey; R H Herzig; R Hutchinson; A Keating; H M Lazarus; G A Milone; S Neudorf; W S Perez; R L Powles; H G Prentice; G Schiller; G Socié; M Vowels; J Wiley; A Yeager; M M Horowitz Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Eric J Chow; Jill H Simmons; Christian L Roth; K Scott Baker; Paul A Hoffmeister; Jean E Sanders; Debra L Friedman Journal: Biol Blood Marrow Transplant Date: 2010-06-01 Impact factor: 5.742
Authors: W Leung; M Hudson; Y Zhu; G K Rivera; R C Ribeiro; J T Sandlund; L C Bowman; W E Evans; L Kun; C H Pui Journal: Leukemia Date: 2000-07 Impact factor: 11.528
Authors: Joanna L Perkins; Alicia S Kunin-Batson; Nancy M Youngren; Kirsten K Ness; Kami J Ulrich; Melissa J Hansen; Anna Petryk; Julia Steinberger; Fiona S Anderson; K Scott Baker Journal: Pediatr Blood Cancer Date: 2007-12 Impact factor: 3.167
Authors: Robert D Murray; Gilbert Wieringa; Jeremy A Lawrance; Judith E Adams; Stephen M Shalet Journal: Clin Endocrinol (Oxf) Date: 2010-10 Impact factor: 3.478
Authors: Brian H Kushner; Stephen S Roberts; Danielle N Friedman; Deborah Kuk; Irina Ostrovnaya; Shakeel Modak; Kim Kramer; Ellen M Basu; Nai-Kong V Cheung Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: Radojka M Savic; Morton J Cowan; Christopher C Dvorak; Sung-Yun Pai; Luis Pereira; Imke H Bartelink; Jaap J Boelens; Robbert G M Bredius; Rob F Wynn; Geoff D E Cuvelier; Peter J Shaw; Mary A Slatter; Janel Long-Boyle Journal: Biol Blood Marrow Transplant Date: 2013-09-09 Impact factor: 5.742
Authors: Danielle Novetsky Friedman; Patrick Hilden; Chaya S Moskowitz; Maya Suzuki; Farid Boulad; Nancy A Kernan; Suzanne L Wolden; Kevin C Oeffinger; Charles A Sklar Journal: Biol Blood Marrow Transplant Date: 2016-12-28 Impact factor: 5.742
Authors: Lynda M Vrooman; Heather R Millard; Ruta Brazauskas; Navneet S Majhail; Minoo Battiwalla; Mary E Flowers; Bipin N Savani; Görgün Akpek; Mahmoud Aljurf; Rajinder Bajwa; K Scott Baker; Amer Beitinjaneh; Menachem Bitan; David Buchbinder; Eric Chow; Christopher Dandoy; Andrew C Dietz; Lisa Diller; Robert Peter Gale; Shahrukh K Hashmi; Robert J Hayashi; Peiman Hematti; Rammurti T Kamble; Kimberly A Kasow; Morris Kletzel; Hillard M Lazarus; Adriana K Malone; David I Marks; Tracey A O'Brien; Richard F Olsson; Olle Ringden; Sachiko Seo; Amir Steinberg; Lolie C Yu; Anne Warwick; Bronwen Shaw; Christine Duncan Journal: Biol Blood Marrow Transplant Date: 2017-04-28 Impact factor: 5.742
Authors: A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera Journal: Clin Transl Oncol Date: 2019-09-21 Impact factor: 3.405
Authors: D Bresters; A Lawitschka; C Cugno; U Pötschger; A Dalissier; G Michel; K Vettenranta; M Sundin; A Al-Seraihy; M Faraci; P Sedlacek; A B Versluys; A Jenkins; P Lutz; B Gibson; A Leiper; M A Diaz; P J Shaw; R Skinner; T A O'Brien; N Salooja; P Bader; C Peters Journal: Bone Marrow Transplant Date: 2016-06-27 Impact factor: 5.483